Fresenius Kabi’s generic Cubicin launches
Fresenius Kabi has introduced its generic Cubicin (daptomycin for injection). The drug is an antibacterial indicated to treat complicated skin and skin structure infections in adults, as well as staph infections in the bloodstream in adults.
The Food and Drug Administration approved the generic Cubicin on April 11, Lake Zurich, Ill.-based Fresenius Kabi said. The generic is available in a single-dose, 500-mg bottle that the company said it would supply as a Novaplus private-label offering for members of Vizient.
Fresenius Kabi noted that it also offers daptomycin for injection through a third party under a previously approved application, and said it would continue to supply that option as well.
No comments found